Vehmeyer, Katalin

[["dc.bibliographiccitation.firstpage","955"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Leukemia Research"],["dc.bibliographiccitation.lastpage","959"],["dc.bibliographiccitation.volume","25"],["dc.contributor.author","Vehmeyer, K."],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Alves, Frauke"],["dc.date.accessioned","2018-11-07T08:29:43Z"],["dc.date.available","2018-11-07T08:29:43Z"],["dc.date.issued","2001"],["dc.description.abstract","The colony-forming capacity of the peripheral blood stem/progenitor cells (PBSC) in different forms of myelodysplastic syndrome (MDS) was investigated. In most cases of refractory anemia (RA) the colony growth of PBSC was definitely reduced as compared to the controls. However, in RA with unfavorable chromosomal aberrations, in refractory anemia with ringed sideroblasts (RARS) and in advanced stages of MDS such as refractory anemia with excess blasts (RAEB) and refractory anemia in transformation (RAEB-t), the number of myeloid progenitor cells increased up to 100-fold. In chronic myelomonocytic leukemia (CMML), the increase was even more marked, up to 350-fold. Although the number of PBSC was strongly elevated, these cells were not able to restore hematopoiesis in vivo. In conclusion, the increase of circulating colony-forming cells (CFC) seems to be associated with disease progression, and thus, the evaluation of PBSC could be an important parameter in the diagnosis of MDS. (C) 2001 Elsevier Science Ltd. All rights reserved."],["dc.identifier.doi","10.1016/S0145-2126(01)00064-9"],["dc.identifier.isi","000171788800004"],["dc.identifier.pmid","11597730"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/16720"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Pergamon-elsevier Science Ltd"],["dc.relation.issn","0145-2126"],["dc.title","Increased peripheral stem cell pool in MDS: an indication of disease progression?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1136"],["dc.bibliographiccitation.issue","7-8"],["dc.bibliographiccitation.journal","TISSUE ENGINEERING"],["dc.bibliographiccitation.lastpage","1147"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Wulf, Gerald G."],["dc.contributor.author","Viereck, Volker"],["dc.contributor.author","Hemmerlein, Bernhard"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Vehmeyer, K."],["dc.contributor.author","Pukrop, Tobias"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Emons, G."],["dc.contributor.author","Truemper, Lorenz H."],["dc.date.accessioned","2018-11-07T10:47:58Z"],["dc.date.available","2018-11-07T10:47:58Z"],["dc.date.issued","2004"],["dc.description.abstract","Progenitor cells with differentiation capacity along multiple mesengenic lineages are attractive tools for numerous purposes in regenerative medicine. Such mesengenic progenitor cells have been isolated from adult mammalian bone marrow, and we here report placental tissue as an alternative source for these cells. By means of dissection/proteinase digestion techniques, high numbers of viable mononuclear cells were harvested from human placenta at term, and a mesenchymal cell population with characteristic expression of CD9, CD29, and CD73 was obtained in culture. The in vitro growth behavior of such placenta-derived mesengenic cells was similar to that of human bone marrow mesengenic progenitor cells. After in vitro propagation for more than three passages the cells were exclusively of maternal origin. Differentiation experiments showed differentiation potential along osteogenic, chondrogenic, adipogenic, and myogenic lineages. In conclusion, we propose human term placenta as an easily accessible, ample source of multipotent mesengenic progenitor cells."],["dc.identifier.doi","10.1089/ten.2004.10.1136"],["dc.identifier.isi","000223851200017"],["dc.identifier.pmid","15363170"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/48088"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Mary Ann Liebert Inc"],["dc.relation.issn","1076-3279"],["dc.title","Mesengenic progenitor cells derived from human placenta"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.volume","96"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Schanz, J."],["dc.contributor.author","Gassmann, W."],["dc.contributor.author","Yilmaz, A."],["dc.contributor.author","Vehmeyer, K."],["dc.contributor.author","Ludwig, W. D."],["dc.contributor.author","Wuchter, C."],["dc.contributor.author","Soeling, Ulrike"],["dc.contributor.author","Pies, A."],["dc.contributor.author","Schulz, T."],["dc.contributor.author","Verbeek, W."],["dc.contributor.author","Bartels, H."],["dc.contributor.author","Binder, Claudia"],["dc.contributor.author","Griesinger, Frank"],["dc.contributor.author","Cliche, K. O."],["dc.contributor.author","Woermann, Bernhard"],["dc.date.accessioned","2018-11-07T09:48:12Z"],["dc.date.available","2018-11-07T09:48:12Z"],["dc.date.issued","2000"],["dc.format.extent","261B"],["dc.identifier.isi","000165256201199"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35257"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.publisher.place","Washington"],["dc.relation.issn","0006-4971"],["dc.title","Amifostin long-term application vs. supportive care - A multicentric phase III trial in patients with low-risk MDS (IPSS < 1.5)."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","862"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Proceedings of the National Academy of Sciences of the United States of America"],["dc.bibliographiccitation.lastpage","867"],["dc.bibliographiccitation.volume","102"],["dc.contributor.author","Hasselblatt, Martin"],["dc.contributor.author","Knerlich, Friederike"],["dc.contributor.author","von Ahsen, N."],["dc.contributor.author","Jacob, Sonja"],["dc.contributor.author","Sperling, S."],["dc.contributor.author","Woldt, H."],["dc.contributor.author","Vehmeyer, K."],["dc.contributor.author","Nave, Klaus-Armin"],["dc.contributor.author","Sirén, A.-L."],["dc.contributor.author","Ehrenreich, H."],["dc.date.accessioned","2017-09-07T11:46:36Z"],["dc.date.available","2017-09-07T11:46:36Z"],["dc.date.issued","2005"],["dc.description.abstract","Central nervous and hematopoietic systems share developmental features. We report that thrombopoietin (TPO), a stimulator of platelet formation, acts in the brain as a counterpart of erythropoietin (EPO), a hematopoietic growth factor with neuroprotective properties. TPO is most prominent in postnatal brain, whereas EPO is abundant in embryonic brain and decreases postnatally. Upon hypoxia, EPO and its receptor are rapidly reexpressed, whereas neuronal TPO and its receptor are down-regulated. Unexpectedly, TPO is strongly proapoptotic in the brain, causing death of newly generated neurons through the Ras-extracellular signal-regulated kinase 1/2 pathway. This effect is not only inhibited by EPO but also by neurotrophins. We suggest that the proapoptotic function of TPO helps to select for neurons that have acquired target-derived neurotrophic support."],["dc.identifier.doi","10.1073/pnas.0406008102"],["dc.identifier.gro","3150545"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/7318"],["dc.language.iso","en"],["dc.notes.status","zu prüfen"],["dc.relation.issn","0027-8424"],["dc.subject","astrocytes; erythropoietin; neurons; differentiation; development"],["dc.title","A hematopoietic growth factor, thrombopoietin, has a proapoptotic role in the brain"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.volume","98"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Steffens, Rainer"],["dc.contributor.author","Alves, Frauke"],["dc.contributor.author","Lorenz, T."],["dc.contributor.author","Vehmeyer, K."],["dc.date.accessioned","2018-11-07T11:23:56Z"],["dc.date.available","2018-11-07T11:23:56Z"],["dc.date.issued","2001"],["dc.format.extent","356A"],["dc.identifier.isi","000172134101503"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/56293"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.publisher.place","Washington"],["dc.relation.issn","0006-4971"],["dc.title","Cytogenetic characterization of stroma cells in MDS and comparison with myeloid cells."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","271B"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.lastpage","272B"],["dc.bibliographiccitation.volume","98"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Gassmann, W."],["dc.contributor.author","Vehmeyer, K."],["dc.contributor.author","Steffens, Rainer"],["dc.contributor.author","Stitz, E."],["dc.contributor.author","Schanz, J."],["dc.contributor.author","Binder, Claudia"],["dc.contributor.author","Griesinger, Frank"],["dc.contributor.author","Ludwig, W. D."],["dc.contributor.author","Wuchter, C."],["dc.contributor.author","Kliche, K. O."],["dc.contributor.author","Hahnfeld, S."],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Woermann, B. J."],["dc.date.accessioned","2018-11-07T11:23:53Z"],["dc.date.available","2018-11-07T11:23:53Z"],["dc.date.issued","2001"],["dc.identifier.isi","000172134201233"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/56282"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.publisher.place","Washington"],["dc.relation.issn","0006-4971"],["dc.title","A phase-III trial in patients with low-risk MDS (IPSS below 1.5) of long-term-amifostine vs. supportive care."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]